Investors

IsomAb was founded in the UK, in March 2022, as a spin-out from the University of Nottingham. It is based at Biocity Nottingham where it has offices and lab space.

IsomAb has an exclusive license from the University of Nottingham to intellectual property and know-how covering VEGF-A antibodies; the work was conducted by Professor David Bates, Professor of Oncology, Centre for Cancer Sciences, University of Nottingham Biodiscovery Institute.

The Company initially raised funds, in 2022, in a pre-Seed round from private investors, the University of Nottingham and SCVC.

In February 2024, the Company successfully completed a Seed round for £7.5m from its original VC investor, SCVC, Broadview Ventures and Mercia Asset Management.

Click on the logos below for further information.